Merck inks deal with Unnatural Products; CG Oncology’s upsized IPO; Locus gets $24M from BARDA
Plus, news about Outlook Therapeutics and Adicet Bio: Merck and Unnatural Products collaborate: Per the deal, Merck will make an undisclosed upfront payment to the Santa Cruz, CA-based biotech and up to $220 million in milestones. The companies plan to develop macrocyclic therapies for cancer. — Jaimy Lee CG Oncology